Michael H. Silverman

2.3k total citations
70 papers, 1.5k citations indexed

About

Michael H. Silverman is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Michael H. Silverman has authored 70 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Molecular Biology and 13 papers in Epidemiology. Recurrent topics in Michael H. Silverman's work include Peptidase Inhibition and Analysis (9 papers), Adenosine and Purinergic Signaling (9 papers) and Clostridium difficile and Clostridium perfringens research (7 papers). Michael H. Silverman is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Adenosine and Purinergic Signaling (9 papers) and Clostridium difficile and Clostridium perfringens research (7 papers). Michael H. Silverman collaborates with scholars based in United States, Israel and Canada. Michael H. Silverman's co-authors include Pnina Fishman, Jason Gotlib, Jörge E. Cortes, Moshe Talpaz, Ayalew Tefferi, Animesh Pardanani, Jolene Shorr, Richard M. Stone, Catriona Jamieson and D. Gary Gilliland and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael H. Silverman

67 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael H. Silverman United States 19 534 335 280 268 261 70 1.5k
Paul Beckett United Kingdom 14 530 1.0× 47 0.1× 225 0.8× 555 2.1× 327 1.3× 58 1.9k
Francis Lacombe France 28 948 1.8× 366 1.1× 952 3.4× 448 1.7× 418 1.6× 82 2.4k
Roberto Passetto Falcão Brazil 26 958 1.8× 357 1.1× 584 2.1× 371 1.4× 420 1.6× 132 2.2k
Vassilios I. Avramis United States 31 1.2k 2.2× 266 0.8× 491 1.8× 454 1.7× 171 0.7× 68 3.0k
Myrna Candelaria Mexico 25 1.4k 2.6× 128 0.4× 129 0.5× 563 2.1× 159 0.6× 88 2.5k
Krish Patel United States 20 540 1.0× 256 0.8× 94 0.3× 514 1.9× 288 1.1× 105 1.7k
H Rochant France 26 604 1.1× 452 1.3× 978 3.5× 183 0.7× 336 1.3× 107 1.9k
Shingo Yano Japan 23 478 0.9× 349 1.0× 956 3.4× 506 1.9× 297 1.1× 173 1.9k
Thierry Dervieux United States 29 526 1.0× 494 1.5× 659 2.4× 259 1.0× 499 1.9× 82 2.9k
Heiko van der Kuip Germany 30 1.0k 1.9× 326 1.0× 462 1.6× 1.3k 4.7× 249 1.0× 60 2.8k

Countries citing papers authored by Michael H. Silverman

Since Specialization
Citations

This map shows the geographic impact of Michael H. Silverman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Silverman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Silverman more than expected).

Fields of papers citing papers by Michael H. Silverman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Silverman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Silverman. The network helps show where Michael H. Silverman may publish in the future.

Co-authorship network of co-authors of Michael H. Silverman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Silverman. A scholar is included among the top collaborators of Michael H. Silverman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Silverman. Michael H. Silverman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friggen, Annemieke H., Michael H. Silverman, Michael R. Barbachyn, et al.. (2025). A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. Nature Communications. 16(1). 9784–9784.
2.
Elkrief, Arielle, Siddhartha P. Duttagupta, Nicolas Marcoux, et al.. (2024). 1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate). Annals of Oncology. 35. S707–S708. 11 indexed citations
3.
Lencioni, Riccardo, Salomon M. Stemmer, Motti Farbstein, et al.. (2024). A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report. Experimental and Therapeutic Medicine. 27(6). 263–263. 2 indexed citations
4.
Zhanel, George G., Michael H. Silverman, Melanie Baxter, et al.. (2024). Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 38. 154–157. 6 indexed citations
5.
Fishman, Pnina, Salomon M. Stemmer, Avital Bareket‐Samish, Michael H. Silverman, & William Kerns. (2023). Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects. Purinergic Signalling. 19(3). 513–522. 11 indexed citations
6.
Haverkate, Manon, Derek R. MacFadden, Nick Daneman, et al.. (2022). A Time Series Analysis Evaluating Antibiotic Prescription Rates in Long-Term Care during the COVID-19 Pandemic in Alberta and Ontario, Canada. Antibiotics. 11(8). 1001–1001. 2 indexed citations
7.
Garey, Kevin W., An Q Dinh, Chenlin Hu, et al.. (2022). Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clinical Infectious Diseases. 75(7). 1164–1170. 25 indexed citations
8.
Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology. 29(7). 789–796. 310 indexed citations
9.
David, Michael, Michael Ziv, Dimitar Gospodinov, et al.. (2011). Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. Journal of the European Academy of Dermatology and Venereology. 26(3). 361–367. 75 indexed citations
10.
11.
12.
Bar‐Yehuda, Sara, Michael H. Silverman, William Kerns, et al.. (2007). The anti-inflammatory effect of A3adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs. 16(10). 1601–1613. 77 indexed citations
13.
Berkenblit, Anna, Ursula A. Matulonis, Joan F. Kroener, et al.. (2005). Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecologic Oncology. 99(1). 50–57. 56 indexed citations
14.
García, Francisco, Karl Ulrich Petry, Laila I. Muderspach, et al.. (2004). ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology. 103(2). 317–326. 142 indexed citations
15.
Carey, Wayne, Steve Warrington, William Kerns, et al.. (2004). Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. International Journal of Clinical Pharmacology and Therapeutics. 42(10). 534–542. 55 indexed citations
16.
Ujhelyi, Michael R., et al.. (2004). Nitrous Oxide Sedation Reduces Discomfort Caused by Atrial Defibrillation Shocks. Pacing and Clinical Electrophysiology. 27(4). 485–491. 4 indexed citations
17.
Silverman, Michael H., Mary Lynne Hedley, Karl Ulrich Petry, & Jeffrey S. Weber. (2002). Clinical Trials in Cervical Intraepithelial Neoplasia: Balancing the Need for Efficacy Data with Patient Safety. Journal of Lower Genital Tract Disease. 6(4). 206–211. 5 indexed citations
18.
Laibovitz, Robert, et al.. (1993). Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca. Cornea. 12(4). 315–323. 90 indexed citations
19.
Nadler, Paul I., et al.. (1991). Safety and Tolerability of Two Percent Cyclosporine (Sandimmune ® ) Ophthalmic Ointment in Normal Volunteers. Journal of Ocular Pharmacology and Therapeutics. 7(4). 301–312. 8 indexed citations
20.
Silverman, Michael H.. (1985). Religious values in the Jewish proper names at Elephantine. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Beckett Breakdown of academic impact, for papers by Francis Lacombe Breakdown of academic impact, for papers by Roberto Passetto Falcão Breakdown of academic impact, for papers by Vassilios I. Avramis Breakdown of academic impact, for papers by Myrna Candelaria Breakdown of academic impact, for papers by Krish Patel Breakdown of academic impact, for papers by H Rochant Breakdown of academic impact, for papers by Shingo Yano Breakdown of academic impact, for papers by Thierry Dervieux Breakdown of academic impact, for papers by Heiko van der Kuip
Rankless by CCL
2026